Finding new drugs requires screening vast numbers of compounds to identify those that interact with a biological target.

BillionToOne, Inc. is disrupting molecular diagnostics, leveraging proprietary smNGS technology for rapid growth and a $5.2B ...

Abbott’s next-gen Oncodetect molecular residual disease (MRD) test detects traces of circulating tumor DNA in a patient’s ...

Powered by whole-genome sequencing and MAESTRO* technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit of ...

The Foundation's CLIA-certified laboratory combines DNA methylation profiling, MGMT status, copy-number variation analysis ...

A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a timely manner for patients with ovarian cancer, emphasizing the need for ...

A retrospective Chinese hospital study found Xpert MTB/RIF was the most sensitive single test for tuberculosis in ...

Pragmatic, Multicenter, Double-Blind Evaluation of Circulating Cancer-Associated Macrophage-Like Cells for Detection of Cancer in Indeterminate Pulmonary Nodules A decision tree for molecular ...

Company profiles cover urine tumor DNA testing products, technologies, applications and market activity.Dublin, Oct. (GLOBE NEWSWIRE) -- "Urine Tumor Deoxyribonucleic Acid (DNA) Testing Global Market ...

Researchers at Dartmouth Hitchcock Medical Center have developed a way to diagnose Lyme disease earlier and more accurately than traditional testing methods. Over the past 30 years, Lyme disease has ...